Lawmakers are laying the groundwork for fresh legislation and regulation aimed at countering Chinese biopharma companies, according to a report from STAT News. The effort comes amid concerns that the Biosecure Act has not prevented the country's ascent in biotechnology.
The Biosecure Act was designed to restrict certain Chinese biotech firms, but its impact has been limited. Critics argue that the current approach has failed to slow China's expanding role in drug development and manufacturing.
Specific details on the proposed measures remain scarce at this stage. The sources indicate that lawmakers are in early planning phases, with no concrete bills or regulations yet introduced. The scope and targets of any new actions are still being defined.
Any new restrictions could reshape supply chains for drug ingredients and research tools. Biopharma companies relying on Chinese partners may face disruptions or higher costs.
The push reflects broader bipartisan concern in Washington about China's influence in critical industries. However, industry groups may push back, warning that overly broad restrictions could hurt innovation and access to medicines.